Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: Outcome and prognostic factors. The Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Transplante Hemopoyético)

Bone Marrow Transplantation

Volumn 36, Issue 4, 2005, Pages 301-306

  Martinez C ^a   Gomez, V ^a   Tomas J F ^a   Parody, R ^a   Sureda, A ^a   Sanz, G ^a   Canizo C ^a   Diez J L ^a   Boque C ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Allogeneic transplantation; Chronic myeloid leukemia; Relapse

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; HYDROXYUREA; IMATINIB;

ADOLESCENT; ADOPTIVE TRANSFER; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SALVAGE THERAPY; SPAIN;

ADOLESCENT; ADULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SPAIN; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 23944452897     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705063     Document Type: Article

References (26)

1. Goldman JM, Apperley JF, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 14: 202-207.
2. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
3. van Rhee F, Szydlo RM, Hermans J et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553-560.
4. Devergie A, Reiffers J, Vernant JP et al. Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse. Bone Marrow Transplant 1990; 5: 379.
5. Martin PJ, Clift RA, Fisher LD et al. HLA-identical marrow transplantation during accelerate phase chronic myelogenous leukemia: analysis of survival and remission duration. Blood 1988; 72: 1978.
6. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for the treatment of chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
7. Higano CS, Chielens D, Raskind W et al. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 1997; 82: 3211-3219.
8. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
9. Cullis JO, Jiang YZ, Scwarer AP et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379-1381.
10. Dazzi F, Szydlo RM, Cross N et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712-2716.
11. Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397-405.
12. Arcese W, Goldman JM, D'Arcangelo E et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Myeloid Leukemia Working Party. European Bone Marrow Transplantation Group. Blood 1993; 82: 3211-3219.
13. Olavarria E, Ottmann OG, Deininger M et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic mycloid leukemia. Leukemia 2003; 17: 1707-1712.
14. Kantarjian HM, O'Brien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590-1595.
15. Guglielmi C, Arcese W, Hermans J et al. Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. Blood 2000; 95: 3328-3334.
16. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087-1092.
17. Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874-878.
18. Hochhaus A, Weisser A, La Rosee P et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000; 14: 998-1005.
19. Olavarria E, Kanfer E, Szydlo R et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001; 97: 1560-1565.
20. Arcese W, Mauro FR, Alimema G et al. Interferon therapy for Ph1-positive CML patients relapsing after T-cell depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 5: 309-315.
21. Steegman JL, Casado LF, Tomas JF et al. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 483-488.
22. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
23. Kantarjian H, Sawyers C, Hochhaus A, et al, The International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
24. Cervantes F on behalf of the IRIS Study Group. Durability of responses to imatinib in newly diagnosed chronic-phase chronic myeloid leukemia (CML): 24-month-update from the IRIS study. Blood 2003; 102 (Suppl. 1): 181a.
25. Mattei D, Saglio G, Gottardi E et al. Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia. Haematologica 2001; 86: 545-546.
26. Raiola AM, Van Lint MT, Valbonesi M et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003; 31: 687-693.